Premium
Stronger Composite Dental Restoration Results from Inclusion of Extracellular Matrix Protection Factor‐2 (ECPF‐2), a New Class of Matrix Metalloprotease 8 (MMP‐8) Inhibitor
Author(s) -
Persky David William,
Tuloglu Nuray,
Ghanta Haritha,
Kitagaito Kaz,
Ciccarelli Haley,
Clauss Gary,
Datillo Victoria,
Selim Abdulhafez,
Ozer Fusun,
D'Angelo Marina
Publication year - 2016
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.30.1_supplement.1039.15
Subject(s) - dentin , matrix metalloproteinase , dentistry , adhesive , extracellular matrix , molar , chemistry , composite number , protease , degradation (telecommunications) , matrix (chemical analysis) , materials science , composite material , biochemistry , enzyme , layer (electronics) , medicine , telecommunications , computer science
Each year in the United States alone, the prevention and restorative treatment of tooth decay exceed costs of $100 billion. A considerable percentage of these costs arise from the need for retreatment and replacement of failed restorations. An innovative means of preventing the failure of dental restorations would ease the financial burden associated with retreatment procedures. Although bacterial enzymes contribute to the degradation of the layer between the composite and dentin, current research indicates a role for endogenous Matrix Metalloprotease‐8 (MMP‐8), a collagenase enzyme, in degradation of the hybrid layer, the region between the dentin and composite resin material. It has been demonstrated that acid etching of the tooth in preparation for administration of the adhesive bonding agent will activate endogenous MMPs in the hybrid layer. The contemporary clinical solution to hybrid‐layer degradation is the use of a nonspecific protease inhibitor, Chlorhexidine Gluconate (0.12%), at the time of treatment. Since MMP‐8 is primarily responsible for the degradation of the organic component of dentin, which is composed predominantly of type I collagen fibers. A more specific targeted protease inhibition should increase bond strength in restorations. To address this notion, our laboratory has developed a proprietary compound, Extracellular Matrix Protection Factor‐2 (ECPF‐2), to specifically inhibit the interaction of MMP‐8 and collagen type I. Utilizing a novel tooth‐restoration model, we treated non‐carious, extracted human third molars with 5μg ECPF‐2 after acid etching and before application of the adhesive. Following placement and curing of the composite material, teeth were either immediately prepared for bond strength testing or first exposed to one‐year of artificial accelerated aging prior to the bond strength testing. Beams (dimensions of 1mm X 1mm) were cut with a milling tool and subjected to microtensile bond strength testing with a single‐speed actuator. Teeth treated with ECPF‐2 exhibited statistically significant increased bond strength (39.6 Megapascals [MPa]) compared to Chlorhexidine treated preparations (20.3 MPa) and bond strength was improved even after one‐year accelerated aging (ECPF‐2 28.9 MPa versus Chlorhexidine 24.0 MPa) even though, as expected, the absolute values were reduced. The enhanced bond strength in ECPF‐2‐treated preparations indicates the importance of this novel inhibitor with respect to clinical and commercially‐available applications in extending the lifespan of dental restorations. Support or Funding Information Center for Chronic Disorders of Aging Small Grant, Philadelphia College of Osteopathic Medicine Schonleber Foundation Grant, University of Pennsylvania